TickerKhojPharmaceuticals · Pharmaceuticals: Major · NSE: KILITCH · data 2026-11-02
Kilitch Drugs (India) Limited
In plain words
Price: 22.8% below its 52-week high of ₹267.9.
Delivery: 50.0% of traded shares were kept for delivery over the last 10 sessions, against 43.3% over the last 60.
Latest results: a net profit of ₹3 cr for the quarter ended Jun 2026 (-4.0% on the same quarter a year earlier).
A description of the data, not a recommendation.
Key figures
Growth
| Revenue (last 12 months) | ₹237 cr |
| Net profit (last 12 months) | ₹30 cr |
| Sales growth, 3 years (yearly) | 19.0% |
| Profit growth, 3 years (yearly) | 42.4% |
At a glance
Promoters 63.8% (unchanged in a year), pledged 0.0%, institutions 0.6%.
P/E 23.7, dividend yield 0.0%. Price relative to earnings and book value (low is cheaper, not better).
ROE 12.5%, ROCE 12.3%, operating margin 13.7%: how much profit it earns on the money it uses.
Debt/equity 0.32, Profit growth 42.4% and sales growth 19.0% a year over 3 years.
Ratings use fixed thresholds on the latest reported figures. They describe the numbers and are not a recommendation.
Strengths and limitations
- Profit grew 42.4% a year over 3 years.
None flagged by these rules.
Picked automatically from the latest reported figures with fixed rules; check the company's filings before relying on them.
Latest results in brief (Q1 FY27)
KILITCH Q1 FY27 results (consolidated figures, as filed on NSE).
Revenue was ₹44.88 crore, up 4% YoY and down 49.9% QoQ.
Net profit was ₹2.91 crore, down 4% YoY and down 80% QoQ.
Operating margin was 6.5% (7.6% a year ago).
EPS was ₹0.83, down 3.5% YoY and down 80.4% QoQ.
KILITCH के Q1 FY27 नतीजे (कंसोलिडेटेड आंकड़े, NSE पर दाखिल)।
राजस्व: ₹44.88 करोड़; पिछले साल की तुलना में 4% की बढ़त, पिछली तिमाही की तुलना में 49.9% की गिरावट।
शुद्ध मुनाफ़ा: ₹2.91 करोड़; पिछले साल की तुलना में 4% की गिरावट, पिछली तिमाही की तुलना में 80% की गिरावट।
ऑपरेटिंग मार्जिन: 6.5% (एक साल पहले 7.6%)।
EPS: ₹0.83; पिछले साल की तुलना में 3.5% की गिरावट, पिछली तिमाही की तुलना में 80.4% की गिरावट।
KILITCHના Q1 FY27 પરિણામો (કન્સોલિડેટેડ આંકડા, NSE પર ફાઇલ કરેલા).
આવક (રેવન્યુ): ₹44.88 કરોડ; ગયા વર્ષની સરખામણીએ 4% વધારો, ગયા ક્વાર્ટરની સરખામણીએ 49.9% ઘટાડો.
ચોખ્ખો નફો: ₹2.91 કરોડ; ગયા વર્ષની સરખામણીએ 4% ઘટાડો, ગયા ક્વાર્ટરની સરખામણીએ 80% ઘટાડો.
ઓપરેટિંગ માર્જિન: 6.5% (એક વર્ષ પહેલાં 7.6%).
EPS: ₹0.83; ગયા વર્ષની સરખામણીએ 3.5% ઘટાડો, ગયા ક્વાર્ટરની સરખામણીએ 80.4% ઘટાડો.
Written from the filed numbers. Not a recommendation.
Smart-money activity
5/100 · Weak over the last ~60 sessions, data 2026-10-30
- Delivery vs usual 0/30: Too few delivery days to compare delivery % (0 of 10); shares delivered not comparable (0 of 12); 0 delivery-spike days (3x usual shares delivered, 40%+ delivery) in the last 20 sessions.
- Bulk/block deals 0/20: No bulk or block deals in the last 90 days.
- Insider / SAST buys 0/15: No insider buy or SAST acquisition filings in the last 90 days. Insider sells are not collected by the site, so only buy filings count.
- Mutual fund holding 0/15: No mutual fund scheme lists this stock. Latest monthly portfolios only (top 60 holdings per scheme); month-on-month change is not stored.
- Accumulation evidence 0/15: No accumulation evidence row (only saved-scan stocks have one; 0 points).
- Promoter pledges 5/5: No promoter pledge filings in 90 days.
A description of recorded activity (delivery, deals, insider buys, fund holding, pledges), not a recommendation. Today's most active stocks.
Story so far
● Results ● Bonus ● Rights
- 13 Aug 26Results Q1 FY27 results: profit −4.0% YoY -5.0% next session
- 15 May 26Results Q4 FY26 results: profit +39.6% YoY +9.0% next session
- 24 Mar 26Bonus Bonus 1:1 (ex-date)
- 11 Feb 26Results Q3 FY26 results: profit −25.7% YoY -10.5% next session
- 13 Nov 25Results Q2 FY26 results: profit −5.0% YoY -2.5% next session
- 13 Aug 25Results Q1 FY26 results: profit +2654.5% YoY -3.9% next session
- 15 Jul 25Rights Rights issue 2:23 · premium ₹347 (ex-date) -5.8% next session
- 19 May 25Results Q4 FY25 results: profit +189.7% YoY +8.6% next session
- 11 Feb 25Results Q3 FY25 results: profit +104.8% YoY +0.2% next session
- 12 Nov 24Results Q2 FY25 results: profit +81.9% YoY +9.0% next session
From official exchange filings and NSE data. How the price moved after an event describes the past, not what comes next.
Quarterly results (consolidated)
| Quarter | Revenue | Net profit | Profit YoY | Op. margin | EPS ₹ |
|---|---|---|---|---|---|
| Jun 2026 | ₹45 cr | ₹3 cr | -4.0% | 6.5% | 0.83 |
| Mar 2026 | ₹90 cr | ₹15 cr | +39.6% | 24.7% | 4.24 |
| Dec 2025 | ₹54 cr | ₹4 cr | -25.7% | 11.4% | 2.5 |
| Sept 2025 | ₹49 cr | ₹8 cr | -5.0% | 10.3% | 4.97 |
Shareholding trend
| Holder | Sept 2026 | Jun 2026 | Mar 2026 | Dec 2025 |
|---|---|---|---|---|
| Promoters | 63.77% | 63.77% | 63.77% | 63.77% |
| Foreign institutions (FII) | 0.11% | 0.12% | 0.00% | 0.00% |
| Domestic institutions (DII) | 0.50% | 0.00% | 0.00% | 0.00% |
| Mutual funds | 0.00% | 0.00% | 0.00% | 0.00% |
| Retail investors | 17.02% | 17.47% | 16.58% | 19.35% |
| Number of shareholders | 12,319 | 12,627 | 11,785 | 12,043 |
Common questions
What was Kilitch Drugs (India) Limited's latest quarterly profit?
Kilitch Drugs (India) Limited reported a net profit of ₹3 cr for the quarter ended Jun 2026 (-4.0% on the same quarter a year earlier), on revenue of ₹45 cr.
How much do promoters hold in Kilitch Drugs (India) Limited?
Promoters held 63.77% of Kilitch Drugs (India) Limited at the end of Sept 2026, with 0.00% of promoter shares pledged.
Is Kilitch Drugs (India) Limited debt-free?
Its latest reported debt-to-equity ratio is 0.32.
What is Kilitch Drugs (India) Limited's P/E ratio?
About 23.7, based on the last 12 months' earnings and a price of ₹206.81 (data 2026-11-02).
What is the 52-week high and low of Kilitch Drugs (India) Limited?
The 52-week high is ₹267.9 and the 52-week low is ₹117.25.
Compared with similar companies
| Company | Price | Market cap | P/E | P/B | ROE | ROCE | Debt/eq. | 1-yr return |
|---|---|---|---|---|---|---|---|---|
| Kilitch Drugs (India) Limited | ₹206.81 | ₹703 cr | 23.7 | — | 12.5% | 12.3% | 0.32 | +6.8% |
| Shree Ganesh Remedies Ltd. | ₹608.6 | ₹792 cr | 50.6 | — | 11.5% | 14.4% | 0.19 | +22.9% |
| Valiant Laboratories Ltd. | ₹128.4 | ₹695 cr | 43.5 | — | -1.2% | 0.2% | 0.15 | +48.6% |
| Hexagon Nutrition Limited | ₹54.34 | ₹664 cr | — | — | 17.7% | 18.7% | 0.14 | +12.6% |
| Wanbury Limited | ₹190.1 | ₹664 cr | 11.7 | — | 64.9% | 31.1% | 1.57 | -25.7% |
| Amanta Healthcare Limited | ₹166.35 | ₹632 cr | 44 | — | 9.4% | 11.5% | 1.11 | +36.9% |
Compare KILITCH with SGRL in detail →
The full analysis has the price chart, every quarterly result with YoY/QoQ growth, the balance sheet and cash flow with an accounting red-flag check, shareholding quarter by quarter with big investors, news, filings and bulk/block deals.
Open KILITCH in TickerKhoj →